Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica. 2023;108:2919–32. https://doi.org/10.3324/haematol.2022.282612.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801–21. https://doi.org/10.1002/ajh.26857.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465–87. https://doi.org/10.1002/ajh.27002.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Pardanani A. Essential thrombocythemia. N. Engl J Med. 2019;381:2135–44. https://doi.org/10.1056/NEJMcp1816082.

Article  PubMed  Google Scholar 

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. https://doi.org/10.1182/blood.2022015850.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ version 2.0: mutation and Karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769–70. https://doi.org/10.1200/JCO.2018.78.9867.

Article  PubMed  Google Scholar 

Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023;13:108. https://doi.org/10.1038/s41408-023-00878-8.

Article  PubMed  PubMed Central  Google Scholar 

Ali H, Bacigalupo A. 2021 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management. Am J Hematol. 2021;96:1532–8. https://doi.org/10.1002/ajh.26349.

Article  PubMed  PubMed Central  Google Scholar 

McLornan D, Eikema DJ, Czerw T, Kroger N, Koster L, Reinhardt HC, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transpl. 2021;56:2160–72. https://doi.org/10.1038/s41409-021-01305-x.

Article  CAS  Google Scholar 

Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol. 2008;83:363–5. https://doi.org/10.1002/ajh.21149.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226–33.

Article  CAS  PubMed  Google Scholar 

Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103:505–11. https://doi.org/10.1046/j.1365-2141.1998.00998.x.

Article  CAS  PubMed  Google Scholar 

James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8. https://doi.org/10.1038/nature03546.

Article  CAS  PubMed  Google Scholar 

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6. https://doi.org/10.1182/blood-2006-04-018879.

Article  CAS  PubMed  Google Scholar 

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270. https://doi.org/10.1371/journal.pmed.0030270.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl J Med. 2013;369:2379–90. https://doi.org/10.1056/NEJMoa1311347.

Article  CAS  PubMed  Google Scholar 

Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 2018;7:82. https://doi.org/10.12688/f1000research.13167.1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tefferi A, Gangat N, Pardanani A, Crispino JD. Myelofibrosis: genetic characteristics and the emerging therapeutic landscape. Cancer Res. 2022;82:749–63. https://doi.org/10.1158/0008-5472.CAN-21-2930.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4:4282–91. https://doi.org/10.1182/bloodadvances.2020002662.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23:1441–5. https://doi.org/10.1038/leu.2009.50.

Article  CAS  PubMed  Google Scholar 

Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27:1322–7. https://doi.org/10.1038/leu.2013.71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, et al. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023;13:3. https://doi.org/10.1038/s41408-022-00780-9.

Article  PubMed  PubMed Central  Google Scholar 

Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, et al. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. Am J Hematol. 2023;98:282–9. https://doi.org/10.1002/ajh.26778.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Pardanani A, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, et al. Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib. Am J Hematol. 2022;97:E433–35. https://doi.org/10.1002/ajh.26714.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Gangat N, Pardanani A. Jaktinib (JAK1/2 inhibitor): a momelotinib derivative with similar activity and optimized dosing schedule. Am J Hematol. 2022;97:1507–9. https://doi.org/10.1002/ajh.26712.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018;8:29. https://doi.org/10.1038/s41408-018-0067-6.

Article  PubMed  PubMed Central  Google Scholar 

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, et al. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia. 2018;32:1035–8. https://doi.org/10.1038/leu.2017.330.

Article  CAS  PubMed  Google Scholar 

Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Pardanani A, et al. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2015;169:77–80. https://doi.org/10.1111/bjh.13262.

Article  CAS  PubMed  Google Scholar 

Pardanani A, Abdelrahman RA, Finke C, Lasho TT, Begna KH, Al-Kali A, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015;29:741–4. https://doi.org/10.1038/leu.2014.306.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8. https://doi.org/10.1182/blood-2013-03-488098.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tefferi A, Pardanani A, Begna K, Al-Kali A Type 1/like Calr mutation in momelotinib-treated patients with myelofibrosis is the most prominent predictor of drug survival and longevity without transplant. Blood Cancer J. 2023; in press.

Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022;36:2261–8. https://doi.org/10.1038/s41375-022-01637-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of Momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35:3844–50.